Inhibition of Intercellular Cytosolic Traffic via Gap Junctions Reinforces Lomustine-Induced Toxicity in Glioblastoma Independent of MGMT Promoter Methylation Status

• Main Authors: Matthias Schneider (Author), Anna-Laura Potthoff (Author), Bernd O. Evert (Author), Marius Dicks (Author), Denise Ehrentraut (Author), Andreas Dolf (Author), Elena N. C. Schmidt (Author), Niklas Schäfer (Author), Valeri Borger (Author), Torsten Pietsch (Author), Mike-Andrew Westhoff (Author), Erdem Güresir (Author), Andreas Waha (Author), Hartmut Vatter (Author), Dieter H. Heiland (Author), Patrick Schuss (Author), Ulrich Herrlinger (Author)
• Format: Book
• Published: MDPI AG, 2021-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Glioblastoma is a malignant brain tumor and one of the most lethal cancers in human. Temozolomide constitutes the standard chemotherapeutic agent, but only shows limited efficacy in glioblastoma patients with unmethylated O-6-methylguanine-DNA methyltransferase (MGMT) promoter status. Recently, it h...